Pallikaris Ioannis G, Kalyvianaki Maria I, Kymionis George D, Panagopoulou Sophia I
Vardinoyannion Eye Institute of Crete, University of Crete, Medical School, Crete, Greece.
J Cataract Refract Surg. 2004 Jun;30(6):1190-7. doi: 10.1016/j.jcrs.2003.10.039.
To evaluate the efficacy and safety of implantation of a new posterior chamber phakic refractive lens (PRL, Ciba Vision Surgical) in highly myopic eyes.
Department of Ophthalmology, Medical School, University of Crete, Vardinoyannion Eye Institute of Crete, Crete, Greece.
Thirty-four myopic eyes of 19 patients were treated for high myopia with implantation of a silicone PRL in the posterior chamber. Mean patient age was 29.0 years +/- 7.9 (SD) (range 18 to 44 years). Manifest refraction in spherical equivalent (MR), uncorrected (UCVA) and best corrected (BCVA) visual acuity (decimal scale), intraocular pressure, higher-order aberrations (root-mean-square [RMS] wavefront error measured with a Shack-Hartmann wavefront sensor WASCA analyzer [Carl Zeiss, Meditec]), possible complications, and subjective symptoms were evaluated.
Phakic refractive lenses were successfully implanted in all eyes. Mean follow-up was 17.17 +/- 3.76 months (range 12 to 24 months). There was a statistically significant reduction in the MR (from -14.70 D +/- 2.65 D [range -20.75 D to -10.50 D] to -0.61 D +/- 0.89 D [range -2.25 D to 1.00 D]) (P<.001). Twenty-seven (79%) and 15 eyes (44%) were within +/-1.00 D and +/-0.50 D of target refraction, respectively. Mean UCVA significantly improved (from counting fingers to 0.62 +/- 0.28 (range 0.08 to 1.20) (P<.001). Mean BCVA also improved from 0.70 +/- 0.24 (range 0.10 to 1.00) to 0.85 +/- 0.24 (range 0.10 to 1.20) (P<0.001). Overall, there was a mean increase in BCVA of 1.5 +/- 1.5 lines (range loss of 2 lines to gain of 5 lines). There was no statistically significant difference in higher-order aberrations after PRL implantation (pre-PRL RMS: 0.18 microm +/- 0.08 microm [range 0.09 microm to 0.38 microm]; post-PRL RMS: 0.21 microm +/- 0.08 microm; [range 0.05 microm to 0.38 microm]) (P =.12).
The PRL showed encouraging results in treating high myopia. Additional patients and longer follow-up period are needed to detect the long-term efficacy and safety of this refractive lens.
评估新型后房型有晶状体眼屈光性晶状体（PRL，Ciba Vision Surgical）植入治疗高度近视眼中的有效性和安全性。
希腊克里特岛克里特大学医学院眼科、克里特岛瓦尔迪诺扬尼翁眼科研究所。
19例患者的34只近视眼中，采用后房型植入硅酮PRL治疗高度近视。患者平均年龄为29.0岁±7.9（标准差）（范围18至44岁）。评估等效球镜度的显验光（MR）、未矫正视力（UCVA）和最佳矫正视力（BCVA）（小数视力表）、眼压、高阶像差（使用Shack-Hartmann波前传感器WASCA分析仪[卡尔蔡司医疗技术公司]测量的均方根[RMS]波前误差）、可能的并发症和主观症状。
所有眼中均成功植入有晶状体眼屈光性晶状体。平均随访时间为17.17±3.76个月（范围12至24个月）。MR有统计学显著降低（从-14.70 D±2.65 D[范围-20.75 D至-10.50 D]降至-0.61 D±0.89 D[范围-2.25 D至1.00 D]）（P<0.001）。分别有27只眼（79%）和15只眼（约44%）的屈光度数在目标屈光度±1.00 D和±0.50 D范围内。平均UCVA显著提高（从数指视力提高到0.62±0.28[范围0.08至1.20]）（P<0.001）。平均BCVA也从0.70±0.24（范围0.10至1.00）提高到0.85±0.24（范围0.10至1.20）（P<0.001）。总体而言，BCVA平均提高了1.5±1.5行（范围从降低2行到提高5行）。PRL植入后高阶像差无统计学显著差异（PRL植入前RMS：0.18μm±0.08μm[范围0.09μm至0.38μm]；PRL植入后RMS：为0.21μm±0.08μm；[范围0.05μm至0.38μm]）（P = 0.12）。
PRL在治疗高度近视方面显示出令人鼓舞的结果。需要更多患者和更长随访期来检测这种屈光性晶状体的长期有效性和安全性。
Zotero 插件